Hengrui Medicine (01276): Injection SHR-A2102 Obtained Drug Clinical Trial Approval Letter

Zhifang Financial APP News, Hengrui Medicine (01276) announced that recently, the company's subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Hengrui Medicine Co., Ltd. have received the approval notice from the National Medical Products Administration for the clinical trial of the injection SHR-A2102. The clinical trial will be conducted in the near future.